Docoh
Loading...

41 results

Filter options loading...
Top filers
Top filing types
Recent filing years
8-K
EX-99.1
PCSA Processa Pharmaceuticals Inc
13 Aug 21
Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update
6:16am
, and targets major milestones in the second half of 2021 HANOVER, Md., August 12, 2021 — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
as a new molecular entity. PCS499 and its metabolites act on multiple pharmacological targets that are important in a variety of conditions. We have
10-Q
2021 Q1
PCSA Processa Pharmaceuticals Inc
13 May 21
Quarterly report
4:30pm
on multiple pharmacological targets that are important in a variety of conditions. We have targeted Necrobiosis Lipoidica (NL) as our lead indication
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
entity. PCS499 and its metabolites act on multiple pharmacological targets that are important in a variety of conditions. We have targeted
10-Q
2020 Q3
PCSA Processa Pharmaceuticals Inc
12 Nov 20
Quarterly report
4:01pm
in many conditions because PCS499 and its metabolites act on multiple pharmacological targets that are important in the treatment of these conditions … or Trental®). PCS499 is classified by FDA as a new molecular entity. PCS499 and its metabolites act on multiple pharmacological targets that are important
424B4
vgxbbq9t
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
l4dr44j1 r3o
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
33bqi 3blois3h9x4pua
16 Sep 20
IPO registration (amended)
8:00pm
10-Q
bxakok uf5g
5 Aug 20
Quarterly report
3:32pm
S-1/A
u883mf2
17 Jul 20
IPO registration (amended)
5:25pm
10-Q
ij907qaw ra76no
15 May 20
Quarterly report
1:23pm
10-K
w2zr65gtpq 9khee4
5 Mar 20
Annual report
7:00pm
S-1
qg2jpq18z167
13 Dec 19
IPO registration
5:32pm
10-Q
ehhgi nx24to
14 Nov 19
Quarterly report
11:45am
10-Q
5p2vb6yj qv6cko
13 Aug 19
Quarterly report
8:00pm
10-Q
rlaq99nsqj0tl
14 May 19
Quarterly report
1:08pm
10-K/A
j12mkd489ttv
5 Apr 19
Annual report (amended)
9:40pm
10-K
e4tvi
28 Mar 19
Annual report
5:25pm
424B3
bckp1f 2zrynpvj0xok
13 Nov 18
Prospectus supplement
9:39pm
10-Q
lcnjoc6m
13 Nov 18
Quarterly report
9:37pm